Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Ítems similars

• Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
  per: Zhao, Bin, et al.
  Publicat: (2018)
• Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
  per: Zhao, Bin, et al.
  Publicat: (2020)
• Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
  per: Zhou, Shi, et al.
  Publicat: (2019)
• Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials
  per: Zhao, Bin, et al.
  Publicat: (2019)
• Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
  per: Larkin, James, et al.
  Publicat: (2017)